Regulators Will Be Wary in Weighing Up Acomplia
The Guardian, in the following story published on January 10, 2005, says that while Sanofi is confident it has a winner in the new anti–obesity drug Acomplia, it can expect close scrutiny during the approval process of the side effects.
Want to lose weight, stop smoking and cut [...]
The L-Marc Research Center (Louisville Metabolic and Atheroscerosis Research Center) in Louisville, Kentucky, is one of the most active metabolic research centers in the world, focusing Acomplia (rimonabant) on Phase II-IV clinical trials of weight-loss drugs.
The clinic is a leading recruiter of participants in weight-loss trials, and [...]
FDA Panel to Weigh Low-Dose Xenical for Over-the-Counter Sale
The anti–obesity drug Xenical, which never quite lived up to its original hype, may get a new lease on life by becoming the first weight-loss medication to move from prescription to over-the-counter status Acomplia (rimonabant) .
GlaxoSmithKline has asked the U.S. Food and Drug Administration for permission to [...]
FDA Approves Diet Drug Alli (Low-Dose Xenical) for Nonprescription Sale
The U.S. Food and Drug Administration, after months of unexplained delay, on Feb. 7th approved Alli — a half-strength version of prescription diet drug Xenical (orlistat) Acomplia (rimonabant) – as the first FDA-approved diet pill to be sold over-the-counter in the United States.
The FDA [...]
Study: Acomplia Weight Loss Modest and Side-Effects Are Concern
Patients taking diet drug Acomplia (rimonabant) can expect to see a only a “modest” weight loss of less than 5 percent of their total body weight and most will remain obese or significantly overweight, according to a study published on the British Medical Journal [...]
Study: Acomplia Weight Loss Modest and Side-Effects Are Concern
Professor Raj Padwal and colleagues found that Acomplia (rimonabant) resulted in a somewhat larger weight loss than Xenical or Meridia, but noted that adverse effects were recorded with all three drugs and in particular, with Acomplia (rimonabant).
“ The most worrying adverse effect was an increased incidence of psychiatric disorders (depression, anxiety, [...]
600 European Patients to Be Enrolled in New Trial of Obesity Drug ATL-962
A second Phase IIb clinical trial has been approved by British regulators to evaluate ATL-962 for the treatment of obesity in up to 600 clinically obese diabetic patients.
The randomised, double-blind trial Acomplia (rimonabant) will compare three doses of ATL-962 with a placebo and with the obesity [...]
Diet Pill Acomplia Seen Becoming ‘Gold Standard’ for Treating Obesity
Diet pill Acomplia (rimonabant), which hasn’t had much good news lately, has been anointed by a leading research firm as the drug that will be the “;clinical gold standard for treating obesity” in 2010.
Even though Acomplia (rimonabant) remains stalled at the FDA, and in [...]
